Ani Pharmaceuticals (ANIP) EBITDA (2011 - 2026)

Ani Pharmaceuticals has disclosed EBITDA across 16 years of filings, most recently posting $38.9 million for Q1 2026.

• EBITDA for Q1 2026 came in at $38.9 million, up 48.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.8 million (up 1814.43% YoY), and the FY2025 annual result was $120.0 million, up 1402.92% from the prior year.
• EBITDA came in at $38.9 million for Q1 2026 at Ani Pharmaceuticals, up from $34.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $38.9 million in Q1 2026 to a low of -$20.5 million in Q3 2024.
• The 5-year median for EBITDA is $9.9 million (2023), against an average of $9.5 million.
• Across the five-year window, EBITDA tumbled 730.38% in 2022 and jumped 894.13% in 2025, its largest moves.
• Ani Pharmaceuticals' EBITDA stood at $1.8 million in 2022, then surged by 269.56% to $6.7 million in 2023, then plunged by 165.09% to -$4.4 million in 2024, then surged by 894.13% to $34.8 million in 2025, then advanced by 11.85% to $38.9 million in 2026.
• The last three EBITDA figures came in at $38.9 million (Q1 2026), $34.8 million (Q4 2025), and $36.2 million (Q3 2025), per Business Quant data.